

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

C m p l t I f K n w n

Application Number	10/607,521
--------------------	------------

Filing Date	06-26-2003
--------------------	------------

First Named Inventor	SCHÄFER
----------------------	---------

Group Art Unit	1014
----------------	------

Examiner Name	R. HENLEY
---------------	-----------

Attorney Docket Number	DEAV2002/0044 - US - NP
------------------------	-------------------------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]


**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with those communications to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Please type a plus sign (+) inside this box → ☒

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/607,521
Filing Date	06-26-2003
First Named Inventor	SCHÄFER
Group Art Unit	11214
Examiner Name	R. Henley
Attorney Docket Number	DEAV2002/0044 - US - NP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HOFMANN et al, RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides, Cell., Vol. 97, 1999, pp 889-901	
		BRALET J et al., Vasoepitidase Inhibitors: an emerging class of cardiovascular drugs, TRENDS in Pharmacological Sciences, 22 (3), March 2001, pp 108-109	
		KILHOVD B et al., The ACE inhibitor ramipril Influences the serum levels of advanced glycation endproducts in high risk patients with coronary artery disease: results from a HOPE substudy, The European Society of Cardiology-XXII Congress, September 1-5, 2001, Stockholm, Sweden, abstract 243	
		LEWIS Edmund J et al., The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy, N. England J. Med., 329, 1993, pp 1456-1462	
		MOLINARO Giuseppe et al., Vasoepitidase inhibitors: a new class of dual zinc metalloepitidase inhibitors for cardiorenal therapeutics, Curr. Opin. Pharmacol., 2002, 2, pp 131-141	
		SINGH R et al., Advanced glycation end-products: a review, Diabetologia, 44, 2001, pp 129-146	

Examiner
Signature

Date
Considered

6/2/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.